<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The accumulation of reactive oxygen species and subsequent oxidative DNA damage underlie the development of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (BO) and its progression to Barrett's <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (BD) and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (BAC) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The promoter regions of 23 genes of the <z:chebi fb="0" ids="16856">glutathione</z:chebi> S-transferase (GST) and <z:chebi fb="0" ids="16856">glutathione</z:chebi> peroxidase (GPX) families were systematically analysed </plain></SENT>
<SENT sid="2" pm="."><plain>Quantitative <z:chebi fb="0" ids="17137">bisulfite</z:chebi> pyrosequencing, real-time RT-PCR, western blot and immunohistochemical (IHC) analysis methods were utilised in this study </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: 14 genes were identified that have CpG islands around their transcription start sites: GSTs (GSTM2-M5, GSTA4, GSTP1, GSTZ1, GSTT2, GSTO1 and GSTO2) and GPXs (GPX1, GPX3, GPX4 and GPX7) </plain></SENT>
<SENT sid="4" pm="."><plain>Analysis of an initial set of 20 primary samples demonstrated promoter DNA hypermethylation and <z:chebi fb="2" ids="33699">mRNA</z:chebi> downregulation of GPX3, GPX7, GSTM2, GSTM3 and GSTM5 in more than half of the BAC samples </plain></SENT>
<SENT sid="5" pm="."><plain>Further analysis of 159 primary human samples (37 <z:mpath ids='MPATH_458'>normal</z:mpath>, 11 BO, 11 BD and 100 BACs) indicated frequent hypermethylation (&gt;or=10% methylation) of GPX3 (62%), GPX7 (67%), GSTM2 (69.1%) and GSTM3 (15%) in BACs </plain></SENT>
<SENT sid="6" pm="."><plain>A significant inverse correlation between DNA methylation and <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression level was shown for GPX3 (p&lt;0.001), GPX7 (p = 0.002), GSTM2 (p&lt;0.001) and GSTM5 (p = 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment of <z:e sem="disease" ids="C0546837" disease_type="Neoplastic Process" abbrv="">oesophageal cancer</z:e> cell lines with <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> and <z:chebi fb="0" ids="46024">trichostatin-A</z:chebi> led to reversal of the methylation pattern and re-expression of these genes at the <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels </plain></SENT>
<SENT sid="8" pm="."><plain>The IHC analysis of GPX3, GPX7 and GSTM2 on a tissue microarray that contained 75 BACs with <z:mpath ids='MPATH_458'>normal</z:mpath> squamous oesophageal samples demonstrated an absent to weak staining in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (52% for GPX3, 57% for GPX7 and 45% for GSTM2) and a moderate to strong immunostaining in <z:mpath ids='MPATH_458'>normal</z:mpath> samples </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Epigenetic inactivation of members of the <z:chebi fb="0" ids="16856">glutathione</z:chebi> pathway can be an important mechanism in Barrett's <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">tumourigenesis</z:e> </plain></SENT>
</text></document>